Zenas BioPharma
The Sr. Director, Regulatory Affairs CMC at Zenas is a senior regulatory leader responsible for overseeing global CMC regulatory strategy to support clinical development of small molecule drug products. The role sits within the Regulatory Affairs organization and partners with Technical Operations, Quality and other stakeholders, reporting to the Vice President, Global Regulatory Affairs CMC. Zenas is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases.
Zenas BioPharma is a biotechnology company focused on discovering and developing therapies for autoimmune and inflammatory diseases. Their stated mission is “Enabling patients with autoimmune diseases to reimagine life,” and they concentrate on finding I&I (inflammation & immunology) innovations. Zenas advances novel drug candidates through discovery and development with the goal of bringing new treatment options to patients and partnering across the biopharma ecosystem.
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Share Price Swings
1 day ago
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 weeks ago
Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed.
Jan 5, 2026
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Zenas BioPharma.
Encouraging Phase II Trial Data Supported Zenas BioPharma (ZBIO) in Q4
3 weeks ago